Conclusions: Systemic administration of sipuleucel-T was associated
with an antigen-specific immune response, and resulted in
localized T and B cell infiltrates in resected prostate cancers at the
interface of the benign and malignant tissue. This is the first report
of immune effects of sipuleucel-T in the prostate tumor microenvironment.
Carol, let me try and understand your insanity. DNDN is struggling to maintain $4 a share and you are suggesting, for no reason whatsoever, that it MAY CLOSE 25% higher by COB. What are you on, black tar heroin or oxycontin. You are completely off the leash.